|
CNBC'S MOST SHARED
- UBS Says It Stays Committed to US Brokerage
- Plan to Sell General Motors' Assets Is Approved
- China Launches Major Step to Yuan Internationalization
- China Says 140 Die in Rioting
- Obama's Russia Visit to Bring Over $1.5 Billion in Deals
- UK Spy Chief's Wife Posts Life on Facebook
- BOJ Shirakawa: Japan Corporate Finance Still Tight
- Alcoa to Post Loss — What Does This Mean?
- Biden: 'We Misread How Bad The Economy Was'
- Market 360: The Week's Best & Worst
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
Text Size 
Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.
The phase III trial comparing gemcitabine chemotherapy and Tarceva with or without Avastin as first-line treatment for advanced pancreatic cancer showed some evidence of clinical activity on secondary endpoints but the trial did not meet the primary endpoint of overall survival, Roche said in a statement.
Data from the AVITA trial are now being further analyzed to determine the extent of benefit of adding Avastin to the Tarceva/gemcitabine combination therapy, Roche said.
Avastin is made by U.S. biotech firm Genentech [DNA
Loading...
()
] , which is majority owned by Swiss drugmaker Roche Holding.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes